Detailed Narrative
Q2 FY26 Performance Overview
India Pesticides Limited reported a robust Q2 FY26, with total revenue reaching INR 295 crores, marking a 26% year-on-year growth. EBITDA for the quarter stood at INR 54 crores, up 37.6% YoY, with margins expanding to 18.3% from 16.6% in Q2 FY25. Net profit increased by 22% to INR 32 crores, achieving a PAT margin of 10.7%. The company also saw its Return on Capital Employed improve to 18.8% from 17.6% in Q2 FY25.
Export and Domestic Market Dynamics
Export sales nearly doubled to INR 140 crores in Q2 FY26, driven by improved offtake in Europe and Australia and increased customer inquiries. Management attributed this success to deeper customer engagement and cost competitiveness. Conversely, domestic revenue remained marginally lower at INR 150 crores due to heavy monsoons impacting the pesticide application cycle. The company aims for a medium-term mix of 55-60% domestic and 40% export.
Capacity Expansion and Strategic Projects
The company achieved a significant milestone by increasing its formulation facility annual output from 6,500 metric tons to 10,000 metric tons, with a revenue potential of INR 400 crores at full utilization. A backward integration project at Sandila for producing 4,000 metric tons of 2,6-DEA, costing INR 65 crores, is progressing to strengthen the supply chain and reduce import dependence. The PEDA plant expansion, though slightly delayed by 15-20 days due to monsoons, is in an advanced stage of construction.
Shalvis Subsidiary Progress and Future Outlook
The Shalvis subsidiary is progressing well, with initial technical grade production of one molecule already started. The company expects Shalvis to contribute meaningfully with around INR 100 crores in revenue by next year, bolstering its specialty chemical roadmap. Future plans include adding 2-3 blocks annually, aiming for INR 1,000 crores from Shalvis alone upon full realization in 3-5 years.
Long-Term Vision and Capital Efficiency
IPL reiterated its long-term vision to achieve INR 3,000 crores in revenue by FY30-31, supported by an integrated manufacturing model and investment in specialty chemistry. The company maintains a zero-debt status, funding all growth through internal accruals, and reported a healthy net cash and cash balance of around INR 80 crores. Capital expenditure for IPL and Shalvis is planned at INR 52 crores and INR 64 crores respectively for the current fiscal year.
Working Capital Management
The company significantly reduced its working capital days from 255 days as of March 2025 to 174 days in September 2025. Management aims for a further reduction of 25-30 days by March 2026, targeting 20 days off inventory and 10-15 days off receivables, to enhance the cash conversion cycle. This improvement reflects ongoing operational discipline and cost efficiencies.